Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

Abstract

The optimal therapy for pure membranous lupus nephritis (MLN) with nephrotic syndrome remains controversial. While the risk of progressive renal deterioration may be small, persistent heavy proteinuria leads to the complications of oedema, hypoalbuminaemia, hyperlipidaemia, hypercoagulability, and venous thrombosis. We examined prospectively the efficacy and tolerability of a sequential immunosuppressive regimen in a cohort of 20 patients with nephrotic syndrome due to pure MLN (WHO Class Va and Vb). Initial therapy comprised prednisolone (0.8 mg/kg/d p.o.) and cyclophosphamide (2–2.5 mg/kg/d p.o.). Prednisolone dosage was gradually tapered to 10 mg/d at 6 months, when cyclophosphamide was replaced by azathioprine (2 mg/kg/d p.o.) as maintenance therapy. Within 12 months of therapy 11(55%) patients had complete remission (CR), 7(35%) patients achieved partial remission (PR) (proteinuria reduced from 6.2 4.0 to 2.0 1.7 g =24 h, P < 0.01), and 2 patients failed to respond. Improvements in proteinuria and serum albumin level were observed after 3–6 months of treatment. Non-responders had lower baseline serum albumin compared to complete responders. Renal function remained stable during follow-up for 73.5 48.9 months. 8 patients had disease relapse at 47 15 months. Early complications (12 months) included herpes zoster (40%), minor respiratory or urinary tract infections (25%), mild leukopenia (15%), and transient amenorrhea (14.3%). 4 of the 20 patients developed pulmonary tuberculosis during follow-up, at 35 24 months after the diagnosis of MLN. 8 patients had hyperlipidaemia. Haemorrhagic cystitis, permanent amenorrhea, vascular complications, and mortality were not observed. We conclude that this sequential immunosuppressive regimen is effective in 90% of patients with MLN and heavy proteinuria. Prudent consideration of the benefits and potential side-effects is required to determine the optimal management for individual patients.

Keywords

azathioprine cyclophosphamide membranous lupus nephritis nephrotic syndrome

Get full access to this article

View all access options for this article.

References

Donadio JV Jr , Burgess JH , Holley KE. Membranous lupus nephropathy:a clinicopathologic study . Medicine (Baltimore) 1977;56: 527-536 .

Donadio JV Jr. Treatment of membranous nephropathy in systemic lupus erythematosus . Nephrol Dial Transplant 1992;7 (Suppl 1): S97-S104 .

Sloan RP , Schwartz MM , Korbet SM , Borok RZ , and the Lupus Nephritis Collaborative Study Group . Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis . J Am Soc Nephrol 1996;7: 299-305 .

Pasquali S , Banfi G , Zucchelli Z et al. Lupus membranous nephropathy:long-term outcome . Clin Nephrol 1993;39: 175-182 .

Baldwin DS , Gluck MC , Lowenstein J , Gallow GR . Lupus nephritis. Clinical course as related to morphologic forms and their transitions . Am J Med 1977;62: 12-30 .

Ordonez JD , Hiatt RA , Killebrew EJ , Fireman BH . The increased risk of coronary heart disease associated with nephrotic syndrome . Kidney Int 1993;44: 638-642 .

Ward MM , Pyun E , Studenski S . Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception cohort . Arthritis Rheum 1995;38: 1492-1499 .

Baldwin DS , Lowenstein J , Rothfield NE et al. The clinical course of the proliferative and membranous forms of lupus nephritis . Ann Intern Med 1970;73: 929-942 .

Chan TM , Li FK , Wong RWS et al. Sequential therapy for diffuse proliferative and membranous lupus nephritis:cyclophosphamide and prednisolone followed by azathioprine and prednisolone . Nephron 1995;71: 321-327 .

10.

Tan EM , Cohen AS , Fries JF et al. The 1992 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982;25: 1271-1277 .

11.

Churg J , Sobin LH ed. Lupus nephritis. In:Renal Disease:Classification and Atlas of Glomerular Diseases. Igaku-Shoin:Tokyo , 1982, pp 127-149.

12.

Appel GB , Silva FG , Pirani CL et al. Renal involvement in systemic lupus erythematosus (SLE):A study of 56 patients emphasizing histologic classification . Medicine (Baltimore) 1978;57: 371-410 .

13.

Adler SG , Johnson K , Louie JS et al. Lupus membranous glomerulonephritis:different prognostic subgroups obscured by imprecise histologic classifications . Mod Pathol 1990;3: 186-191 .

14.

Schwartz MM , Kawala K , Roberts JL et al. Clinical and pathological features of membranous glomerulonephritis of systemic lupus erythematosus . Am J Nephrol 1984;4: 301-311 .

15.

Donadio JV , Holley KE , Ferguson RH , Ilstrup DM . Treatment of lupus nephritis with prednisone and combined prednisone and cyclophosphamide . N Engl J Med 1978;299: 1151-1155 .

16.

Cameron JS , Turner DR , Ogg CS et al. Systemic lupus with nephritis:A long-term study . Q J Med 1979;48: 1-24 .

17.

Austin HA , Boumpas DT . Treatment of lupus nephritis . Semin Nephrol 1996;16: 527-535 .

18.

Urowitz MB , Bookman AAM , Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus . Am J Med 1976;60: 221-225 .

19.

Imperiale TF , Goldfarb S , Berns JS . Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials . J Am Soc Nephrol 1995;5: 1553-1558 .

20.

Austin HA III et al. Therapy of lupus nephritis:controlled trial of prednisolone and cytotoxic drugs . N Eng J Med 1986;314: 614-619 .

21.

Pohl MA , Lan SP , Berl T , and the Lupus Nephritis Collaborative Study Group . Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis . Ann Intern Med 1991;114: 924-929 .

22.

Department of Health Annual Report 1996-9 , Hong Kong Government .

23.

Radhakrishnan J , Kunis CL , Agati VD , Appel GB . Cyclosporine treatment of lupus membranous nephropathy . Clin Nephrol 1994;42: 147-154 .

24.

Espinoza LR , Jara LJ , Martinez Osuna P et al. Refractory nephrotic syndrome in lupus nephritis:favorable response to indomethacin therapy . Lupus 1993;2: 9-14 .